Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1997-1-23
|
pubmed:abstractText |
We have used three complementary in vitro systems to express the human phenylalanine hydroxylase (PAH) gene at high levels. Recombinant PAH was expressed in Escherichia coli (as a fusion protein), in human kidney cells and in a cell-free in vitro transcription-translation system. These systems were used to characterize a novel kinetic variant form (D143G) of the enzyme. The recombinant D143G mutant enzyme had the same physicochemical properties as the wild-type PAH and was stable when expressed in eukaryotic cells. Enzyme activity studies of the D143G mutant enzyme, produced in the three expression systems, revealed a kinetic variant form with reduced affinity for L-Phe (about 2.4-fold increase in the S0.5 value) as well as reduced affinity for tetrahydrobiopterin (BH4) (about 2-fold increase in the apparent Km). At standard assay conditions (1 mM L-Phe, t5 microM BH4) the residual activity of the mutant enzyme was high and variable (52%, 33%, and 102%) when analysed in the three different systems. The high residual activities of the mutant enzyme obtained at these conditions were not in agreement with the classical PKU phenotype found in a patient compound heterozygous for the termination mutation G272X and the novel D143G mutation. However, when the D143G mutant enzyme was assayed at lower concentrations of L-Phe (100-300 microM) and BH4 (10 microM) the residual activities were compatible with severely reduced hydroxylation of L-Phe and the classical PKU phenotype.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1059-7794
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
236-46
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:8889583-Aspartic Acid,
pubmed-meshheading:8889583-Cell Line,
pubmed-meshheading:8889583-Cloning, Molecular,
pubmed-meshheading:8889583-Escherichia coli,
pubmed-meshheading:8889583-Exons,
pubmed-meshheading:8889583-Genetic Variation,
pubmed-meshheading:8889583-Glycine,
pubmed-meshheading:8889583-Humans,
pubmed-meshheading:8889583-Kidney,
pubmed-meshheading:8889583-Kinetics,
pubmed-meshheading:8889583-Mutagenesis, Site-Directed,
pubmed-meshheading:8889583-Phenylalanine Hydroxylase,
pubmed-meshheading:8889583-Phenylketonurias,
pubmed-meshheading:8889583-Polymerase Chain Reaction,
pubmed-meshheading:8889583-Recombinant Fusion Proteins
|
pubmed:year |
1996
|
pubmed:articleTitle |
PKU mutation (D143G) associated with an apparent high residual enzyme activity: expression of a kinetic variant form of phenylalanine hydroxylase in three different systems.
|
pubmed:affiliation |
Department of Medical Genetics, Haukeland Hospital, University of Bergen, Norway.
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|